Evidence map›Paper›PMID 42645365›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Claudin 18.2 Expression and Outcomes of First-Line Chemoimmunotherapy in HER2-Negative Gastric or Gastroesophageal Junction Cancer: A Single-Center Retrospective Study.

Run Bao, Jing Qin, Rong Zhang, Zhuo Xu, Jiahao Liu, Jiaofeng Shen, Shunji Zhang, Yusong Zhang, Hong Zhu, Chunyan Huang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Run BaoDepartment of Gastroenterology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Jing QinDepartment of Oncology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Rong ZhangDepartment of Respiratory Medicine, Hangzhou First People's Hospital Tonglu Campus, Hangzhou 311500, China.
Zhuo XuDepartment of Oncology, Zhangjiagang First People's Hospital, Suzhou 215600, China.
Jiahao LiuDepartment of Pathology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Jiaofeng ShenDepartment of Oncology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Shunji ZhangDepartment of Oncology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Yusong ZhangDepartment of Oncology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Hong ZhuDepartment of Oncology, First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Chunyan HuangDepartment of Chronic Non-Communicable Diseases, Suzhou Center for Disease Control and Prevention, Suzhou 215004, China.
Yan LuDepartment of Chronic Non-Communicable Diseases, Suzhou Center for Disease Control and Prevention, Suzhou 215004, China.
Tianhua LiuDepartment of Gastrointestinal Surgery, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Wangyang PuDepartment of Oncology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.ORCID 0000-0001-9047-1129

Funding

China Zhongguancun Precision Medicine Science and Technology Foundation GYLZH70Suzhou Medical College of Soochow University - Qilu Medical Research Fund 24QL200107The Second Affiliated Hospital of Soochow University Scientific Research Pre-Research Fund SDFEYGZ2322Wu Jieping Medical Foundation 320.6750.2025-06-271
6 · The paper itself

Abstract

This study aimed to characterize claudin 18.2 (CLDN18.2) expression in HER2-negative gastric or gastroesophageal junction cancer (GC/GEJC) and to evaluate whether CLDN18.2 status is associated with clinicopathological features and outcomes after first line chemoimmunotherapy. We retrospectively analyzed 189 patients with HER2-negative GC/GEJC treated at our institution from October 2019 to September 2024. CLDN18.2 expression was assessed by immunohistochemistry using two prespecified positivity thresholds: moderate to strong membranous staining (2+) in ≥40% or ≥75% of tumor cells. CLDN18.2 positivity was observed in 92/189 patients (48.7%) using the ≥40% threshold and 69/189 (36.5%) using the ≥75% threshold. PD L1 CPS ≥ 5 was less frequent in CLDN18.2 positive than in CLDN18.2 negative tumors at both thresholds (≥40%: 8.7% vs. 23.7%,

Indexed as

ClaudinsEsophageal NeoplasmsEsophagogastric JunctionImmunotherapyStomach NeoplasmsAgedErb-b2 Receptor Tyrosine KinasesFemaleHumansMaleMiddle AgedRetrospective StudiesClaudinsCLDN18 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinaseschemoimmunotherapyClaudin 18.2gastric cancergastroesophageal junction cancerPD-L1

Identifiers

PMID42645365
PMCPMC13510881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.